About Us | Contact Us |        

Optimizing The Management of Type 2 Diabetes Mellitus: Integrating Injectable Anti-diabetes Therapies into Clinical Care

Endocrinology
Curriculum:
Optimizing the Management of Type 2 Diabetes Mellitus
Credits:
1.5 AMA PRA Category 1 Credit(s)
Launch Date:
February 11, 2020
Expiration Date:
February 11, 2021

Primary Audience:

Primary care, endocrinology physicians, physician assistants, nurse practitioner, nurses, other healthcare providers in the management of T2DM

Relevant Terms:

Diabetes, Type 2 Diabetes Mellitus, Injectable Diabetes Therapy, Pharmacological Therapy, GLP-1 RA therapy, Insulin Therapy

Richard S. Beaser, MD (Course Director)

Senior Staff Physician
Medical Director, Continuing Medical Education
Senior Strategic Advisor, Education Programs
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Beaser received his medical degree in 1977 from Boston University School of Medicine and completed his internal medicine residency at the University of Massachusetts Medical Center in Worcester, as well as fellowships in diabetes and endocrinology at the Joslin Diabetes Center, Boston and Lahey Clinic Medical Center, Burlington, MA. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982, where he has since held numerous positions, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, and Coordinator of the Patient Education Section.
  
Dr. Beaser has authored multiple editions of Joslin Diabetes Manual (1989), Outsmarting Diabetes (1994), The Joslin Guide to Diabetes (1995, 2005), and the Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers (2001, 2003, 2007, 2010, 2014).  He has also authored and co-authored articles for The American Journal of Managed Care, Diabetes Spectrum, Endocrinology and Metabolism Clinics of North America, and the American Journal of Preventive Medicine.  He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial.

Dr. Beaser is a well-known national lecturer/faculty on clinical diabetes and its comorbidities and is active in the clinical practice of adult diabetes at the Joslin Diabetes Center. Dr. Beaser founded the Professional Education Department at the Joslin Diabetes Center in the early 1990s, serving as its academic leader to extend the many educational outreach efforts of this world-recognized facility.  His current activities include developing, overseeing, and/or advising on the academic development/production of many of Joslin’s external educational projects which target physicians, other medical professionals, and patients.

Bruce W. Bode, MD, FACE

Clinical Associate Professor of Medicine
Emory University School of Medicine
President and CEO
Atlanta Diabetes Associates
Atlanta, Georgia

Dr Bruce Bode is a diabetes specialist with Atlanta Diabetes Associates in Atlanta, Georgia, and is currently a faculty member at Emory University as a Clinical Associate Professor in the Department of Medicine. He is currently CEO and President of Atlanta Diabetes Associates that employs 5 endocrinologists, 13 Nurse Practitioners and Physician Assistants, and 12 research coordinators.  Dr Bode earned his medical degree from Emory University School of Medicine and completed an internship and residency in internal medicine at Emory University Affiliated Hospitals and a fellowship in diabetes with Paul C. Davidson, MD. 

Dr Bode is a prolific writer with over 300 articles and books in the field of diabetes that addresses current and future therapies. He has contributed to and/or served on the review committee for Diabetes Care, Diabetes Technology and Therapeutics, The Diabetes Educator, Endocrine Practice, Expert Reviews in Endocrinology and Metabolism, Future Drugs, Diabetes Research and Clinical Practice, and the Journal of Diabetes Science and Technology, among many others. He currently serves on the editorial review committee for Touch Endocrinology.

Dr Bode has a strong affinity for working with children and young adults with diabetes and is considered one of the leading experts in the world on insulin delivery, glucose sensing, and the development of the artificial pancreas. He is very active in clinical research for new diabetes products including pharmacological agents to prevent diabetes and control glucose and new insulins and glucose sensors.

Mark W. Stolar, MD

Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Dr Mark W. Stolar is an Associate Professor of Clinical Medicine at the Feinberg School of Medicine, Northwestern University, in Chicago, Illinois. Dr Stolar earned his medical degree at the University of Illinois in Chicago. He completed his fellowship in endocrinology at the Northwestern University Medical School and his residency in internal medicine at Lutheran General Hospital in Park Ridge, Illinois. Dr Stolar is board certified in endocrinology, diabetes, and metabolism, and internal medicine.

Dr Stolar has authored clinical articles for Mayo Clinic Proceedings and the American Journal of Health-System Pharmacy, and co-authored many more for The Journal of Clinical Endocrinology and Metabolism, Diabetes Care, and Metabolism: Clinical and Experimental. A highly regarded speaker, Dr Stolar is actively involved in physician education in the area of diabetes and cardiovascular disease and has both written and presented in the United States and internationally in those areas. He is currently president of the Endocrine Fellows Foundation and is actively involved in enhancing career opportunities for trainees in endocrinology. Dr Stolar’s academic interests include diabetes, lipid disorders, and thyroid disease.

Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP

Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist, Joslin Diabetes Center
Boston, Massachusetts

Dr. Segal is a Professor of Pharmacy Practice at the Massachusetts College of Pharmacy and Health Sciences (MCPHS) and is also the clinical pharmacist at the Joslin Diabetes Center, in Boston, Massachusetts. Dr. Segal completed her doctorate of pharmacy at Drake University in Des Moines, Iowa. After completing post-doctorate residencies at the Medical Center at Princeton and the Medical University of South Carolina, Dr. Segal taught for several years at the University of New Mexico. In 2007, she joined MCPHS and established clinical pharmacy services at Joslin.

Dr. Segal is the first clinical pharmacist at the Joslin Diabetes Center, where she assists in provider, staff, and continuing professional education; patient education and care; and clinical trials, in addition to serving on the institutional review board for human studies and guideline committees. She is also one of the first pharmacists to receive Certified Diabetes Technology Clinician certification. Dr. Segal is a fellow of the American College of Clinical Pharmacy and an active member of several national organizations: the Endocrine and Metabolism and Ambulatory Care Practice and Research Networks of ACCP; the Diabetes and Cardiovascular Disease and Health Care Delivery and Quality Improvement interest groups; and the Women’s Interprofessional Network of American Diabetes Association.
 
Dr. Segal’s research focuses on the care of adults with diabetes. She has authored or coauthored numerous publications for the Journal of Diabetes Science and Technology, Endocrinology and Metabolism Clinics of North America, Diabetes Care, and the American Journal of Health-System Pharmacy, among many others, on topics including diabetes in older adults and concentrated insulin and pharmacotherapy guidelines for patients with type 2 diabetes. She has also authored book chapters for the Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers, Endocrine and Metabolic Medical Emergencies: A Clinician’s Guide, and Geriatric Diabetes.
1. DESCRIBE the pathophysiology and progression of T2DM as it relates to the eventual need for injectable therapies to manage blood glucose.
2. IDENTIFY provider and patient-derived barriers that contribute to clinical inertia regarding the initiation and intensification of injectable therapy in T2DM.
3. COMPARE the efficacy, safety, and clinical indications of basal insulin, injected and evolving oral GLP1-RAs, and GLP1-RA/insulin FRCs+ as part of T2DM treatment.
4. RECOGNIZE clinical scenarios in which progression to an injectable anti-diabetes therapy may be appropriate.
5. INCORPORATE shared decision-making strategies to facilitate the appropriate utilization of injectable therapies as part of overall T2DM management.

Sponsored by

This activity is supported by an educational grant from Novo Nordisk Inc.

GOAL
The goals of this activity are to provide guidance about the clinical use of newer injectable therapies manage patients with T2DM and to offer an opportunity for clinicians to improve their skills in patient evaluation and therapeutic implementation of treatment programs, leveraging multidisciplinary treatment support, utilizing these newer pharmacotherapeutic options.
 
TARGET AUDIENCE
Primary care and endocrinology physicians, physician assistants, nurse practitioner, nurses, and other healthcare providers who participate in the management of patients with T2DM. No prerequisites required.
 
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and ASiM CE LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.
 
CREDIT DESIGNATION STATEMENT
Joslin Diabetes Center designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
PARTICIPATING FACULTY
Richard S. Beaser, MD (Course Director)
Senior Staff Physician
Medical Director, Continuing Medical Education
Senior Strategic Advisor, Education Programs
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP
Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist, Joslin Diabetes Center
Boston, Massachusetts
 
Bruce W. Bode, MD, FACE
Clinical Associate Professor of Medicine
Emory University School of Medicine
Diabetes Specialist
Atlanta Diabetes Association
Atlanta, Georgia
 
Mark W. Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
 
FINANCIAL DISCLOSURES
Disclosures of Conflicts of Interest
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.
 
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
 
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.
 
The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.
 
The faculty and planning committee members for this program have disclosed the following:
 
Faculty
  • Richard S. Beaser, MD, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
  • Bruce W. Bode, MD, FACE, Clinical Associate Professor of Medicine, Emory University School of Medicine, has no relevant financial relationships with regard to this activity.
  • Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP, Professor of Pharmacy Practice, MCPHS University Clinical Pharmacist, has no relevant financial relationships with regard to this activity.
  • Mark W. Stolar, MD, Associate Professor of Clinical Medicine, Feinberg School of Medicine, Northwestern University, has no relevant financial relationships with regard to this activity.
 
Joslin CME Advisory Committee
  • Jessica Marshall, PhD, Executive Medical Director, ASiM, CE LLC, has no relevant financial relationships with regard to this activity.
  • Wendy Gloffke, PhD, Medical Writer, Medical Writing & Communications, has no relevant financial relationships with regard to this activity.
  • Lisa Mangione, Senior Medical Editor, ASiM CE LLC, has no relevant financial relationships with regard to this activity.
  • Joslin CME Advisory Committee
  • Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
  • Nuha El Sayed, MD, Staff Physician and Medical Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
  • Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center, holds stock in Tandem Diabetes Care.
  • Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.
  • Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP , Clinical Pharmacist, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
  • Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships 
  • Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.
 
METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
 
CONTACT INFORMATION
Please send content inquiries to: cme@joslin.harvard.edu.
 
FEE INFORMATION
There is no fee for this educational activity.

 

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above